查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1830376

合成激素市場（按激素類別、應用、技術和最終用戶分類）—2025-2032 年全球預測

Synthetic Hormones Market by Hormone Class, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年合成荷爾蒙市場規模將成長至 31.1 億美元，複合年成長率為 14.89%。

主要市場統計數據
基準年2024年 10.2億美元
預計2025年 11.7億美元
預測年份：2032年 31.1億美元
複合年成長率（%） 14.89%

合成激素領域的權威概況，重點介紹臨床促進因素、技術進步以及產業相關人員的策略要務

合成激素領域正處於臨床需求、技術創新和不斷變化的監管格局的交匯點。近期趨勢表明，合成胜肽及其類似物正在加速發展，同時人們也更加重視安全性、便捷的給藥方式和價格承受能力。隨著遠端醫療和居家醫療的興起，病患就醫路徑也隨之演變，製造商和醫療保健提供者必須在複雜的生產需求、嚴格的品管和競爭激烈的價格壓力之間取得平衡。

重組DNA技術和複雜化學合成的轉化醫學進展，使得治療方法種類更加豐富，但也帶來了新的生產依賴和監管觸點。同時，人口結構趨勢、不斷發展的臨床指南以及患者對微創給藥的偏好，正在重塑避孕、糖尿病、生長激素缺乏症、更年期和甲狀腺疾病的臨床實踐模式。這些動態要求相關人員重新思考其產品組合策略、生產佈局和通路互動模式。

對於尋求將科學進步轉化為持續商業性成果的組織而言，清晰的策略至關重要。本報告提煉了最重要的變革，識別了基於細分領域的影響，並提出了切實可行的建議，以幫助企業在掌握科學和市場發展勢頭的同時規避營運風險。

對重塑荷爾蒙療法發展途徑和商業策略的技術、監管和管道變化的引人注目的分析

過去十年，合成荷爾蒙的開發、生產和輸送方式發生了翻天覆地的變化。重組DNA方法和細胞表現系統的創新拓展了治療分子的可行範圍，使生技藥品的純度更高，批次間性能更穩定。同時，製劑科學和輸送裝置的進步降低了自我給藥的門檻，將荷爾蒙療法的覆蓋範圍從傳統的臨床環境擴展到居家醫療和遠端醫療模式。

管理體制日益精細，圍繞生物相似藥對比策略和激素類藥物長期使用的藥物藥物安全檢測審查日益嚴格。這些監管變化促使人們更加重視臨床證據的產生和上市後安全監測，進而影響研發進度和商業性定位。同時，供應鏈的韌性也變得至關重要，製造商正在實現原料供應商的地域多元化，並投資於冗餘產能，以緩解地緣政治和物流中斷的影響。

數位藥局和以處方箋為基礎的線上配藥平台正在改變患者獲取和依從性模式，而專科診所和綜合醫療服務提供者正在嘗試訂閱模式和捆綁式醫療服務。總而言之，這些變化要求產業參與者調整其研發、監管策略、製造投資和商業模式，以保持成長並應對新興風險。

深入檢驗2025 年關稅如何迫使整個合成激素價值鏈進行供應鏈重組、採購多樣化和定價策略

2025年累積關稅的實施對合成荷爾蒙生態系統的成本結構、供應商選擇和策略採購產生了重大影響。依賴跨境供應鏈的製造商面臨新的激勵機制，需要重新評估其供應商組合，在可行的情況下優先考慮在地採購，並重新協商長期獎勵，以吸收或緩解關稅相關的成本壓力。此類調整通常需要重新調整籌資策略，以支援在優惠貿易區內營運的供應商，並探索近岸外包選項，以降低進口關稅和物流波動帶來的風險。

製藥公司還必須權衡遷移某些生產流程與維持供應連續性之間的營運利弊。對一些製藥公司而言，雖然資本密集型，但事實證明，為確保關鍵中間體和生技藥品的產量，採用先進的生產流程具有戰略意義。在其他情況下，投資雙源框架和庫存緩衝提供了更大的靈活性，以適應關稅波動。同時，付款人和經銷商已開始更密切地審查定價和報銷動態，這促使一些製造商加快成本效益計劃，並追求強調醫療總成本而非僅僅單位成本的價值證明。

整體而言，關稅環境凸顯了綜合商業和供應鏈策略的必要性，這種策略可以抵禦政策主導的衝擊，同時保持不同醫療環境中荷爾蒙療法的可及性和品質。

綜合細分分析，將荷爾蒙類別、治療用途、實行技術和最終用戶管道與可操作的策略重點連結起來

深入的細分能夠明確治療和商業機會所在，以及營運風險集中。根據荷爾蒙類別，市場涵蓋雌激素、胰島素和甲狀腺，每種激素代表不同的臨床路徑和生產方式，需要量身定做的監管策略和給藥方法。根據應用，市場涵蓋避孕、糖尿病、生長激素缺乏症、更年期和甲狀腺疾病；避孕涵蓋口服複方避孕藥和純孕激素避孕藥；生長激素缺乏症涵蓋成人和兒童生長激素缺乏症；更年期症狀涵蓋潮熱、骨質疏鬆症和陰道萎縮；甲狀腺疾病涵蓋甲狀腺功能亢進和甲狀腺機能低下症和甲狀腺機能低下症和甲狀腺功能低下。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 使用生物合成雌二醇和睪固酮類似物的個人化荷爾蒙補充療法的激增
  • 透過整合人工智慧主導的分子設計加速新型合成胜肽激素的發現
  • 監管部門的核准推動了合成 GnRH 類似物的長效緩釋製劑的採用
  • 增加對植物來源生物合成途徑的投資，實現永續的黃體素生產
  • 擴展具有超快速作用特性的合成胰島素類似物，以實現精確的血糖控制
  • 滲透性促進劑和奈米載體開發口服合成胜肽激素
  • 遠端醫療醫療處方平台的成長正在推動對家用荷爾蒙療法套件的需求
  • 製藥公司和生物技術公司之間的策略合作，以擴大化學酶激素合成
  • 合成人體生長荷爾蒙持續皮下輸送系統的開發
  • 市場轉向實驗室培養的微生物發酵途徑，以實現經濟高效的 hGH 生產

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 合成荷爾蒙市場荷爾蒙類別

  • 雌激素
  • 胰島素
  • 甲狀腺

9. 合成荷爾蒙市場（依應用）

  • 避孕
    • 複方口服避孕藥
    • 僅含黃體素的避孕藥
  • 糖尿病
  • 生長激素缺乏症
    • 成人生長激素缺乏症
    • 兒童生長激素缺乏症
  • 更年期症狀
    • 熱潮紅
    • 骨質疏鬆症
    • 陰道萎縮
  • 甲狀腺疾病
    • 甲狀腺功能亢進
    • 甲狀腺機能低下症

10. 合成荷爾蒙市場（依技術）

  • 化學合成
    • 液相合成
    • 固相合成
  • 重組DNA技術
    • 細菌表現系統
    • 哺乳動物細胞表現系統
    • 酵母表現系統

第 11 章。 合成激素市場（按最終用戶）

  • 診所
    • 綜合診所
    • 專科診所
  • 居家照護環境
    • 護理服務
    • 自我管理
  • 醫院
    • 私立醫院
    • 公立醫院
  • 網路藥局
    • 在商店
    • 處方箋
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

第 12 章。按地區分類的合成荷爾蒙市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 合成荷爾蒙市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章 各國合成荷爾蒙市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • Sanofi SA
    • AstraZeneca PLC
    • Novo Nordisk A/S
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ferring BV
    • Endo Pharmaceuticals Inc.
    • Lupin Pharmaceuticals Inc.
    • IBSA Institute Biochimique SA
Product Code: MRR-431C35F6C25D

The Synthetic Hormones Market is projected to grow by USD 3.11 billion at a CAGR of 14.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.02 billion
Estimated Year [2025] USD 1.17 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 14.89%

An authoritative overview of the synthetic hormones landscape highlighting clinical drivers, technological advances, and strategic imperatives for industry stakeholders

The synthetic hormones landscape sits at the intersection of clinical need, technological innovation, and shifting regulatory frameworks. Recent years have witnessed accelerated development of engineered peptides and analogs alongside renewed emphasis on safety, delivery convenience, and affordability. As patient pathways evolve through expanded telehealth adoption and greater home-based care, manufacturers and healthcare providers must reconcile complex production demands with stringent quality controls and competitive pricing pressures.

Translational progress in recombinant DNA techniques and refined chemical synthesis has enabled a broader therapeutic palette, but it also introduces new manufacturing dependencies and regulatory touchpoints. Concurrently, clinical practice patterns for contraception, diabetes, growth hormone deficiency, menopausal care, and thyroid disorders are being reshaped by demographic trends, evolving clinical guidelines, and patient preferences for less invasive administration. These dynamics require stakeholders to rethink portfolio strategies, manufacturing footprints, and channel engagement models.

Strategic clarity is now essential for organizations that seek to convert scientific advances into durable commercial outcomes. This report distills the most consequential shifts, identifies segmentation-driven implications, and offers actionable recommendations to navigate operational risks while capturing momentum from scientific and market developments.

Compelling analysis of converging technological, regulatory, and channel shifts that are reshaping development pathways and commercial strategies for hormone therapies

The past decade has brought transformative shifts that are redefining how synthetic hormones are developed, manufactured, and delivered. Innovations in recombinant DNA methods and cell expression systems have expanded the feasible range of therapeutic molecules, enabling higher purity biologics and more consistent batch-to-batch performance. At the same time, advances in formulation science and delivery devices have reduced barriers to self-administration, thereby extending the reach of hormone therapies beyond traditional clinical settings into homecare and telemedicine-facilitated models.

Regulatory regimes are becoming more nuanced, with agencies intensifying scrutiny on comparator strategies for biosimilars and on pharmacovigilance for long-term hormone use. This regulatory tightening is fostering greater emphasis on clinical evidence generation and post-market safety surveillance, which in turn influences development timelines and commercial positioning. Concurrently, supply chain resilience has moved to the forefront, with manufacturers seeking geographic diversification of raw material suppliers and investing in redundant manufacturing capacities to mitigate geopolitical and logistic disruptions.

Market channels are also shifting: digital pharmacies and prescription-based online dispensing platforms are altering patient acquisition and adherence patterns, while specialty clinics and integrated care providers are experimenting with subscription models and bundled care pathways. Taken together, these shifts demand that industry participants align R&D, regulatory strategy, manufacturing investments, and commercial models to sustain growth and manage emerging risks.

In-depth examination of how 2025 tariff measures have compelled supply chain reconfiguration, sourcing diversification, and pricing strategies across the synthetic hormones value chain

The implementation of cumulative tariffs in 2025 has had material implications for cost structures, supplier selection, and strategic sourcing within the synthetic hormones ecosystem. Manufacturers that rely on cross-border supply chains faced renewed incentives to reassess their vendor portfolios, prioritize local content where feasible, and renegotiate long-term agreements to absorb or mitigate tariff-related cost pressures. These adjustments often entailed reconfiguring procurement strategies to favor suppliers operating within preferential trade zones or exploring nearshoring options to reduce exposure to import duties and logistical volatility.

Pharmaceutical companies also had to weigh the operational trade-offs between relocating certain production steps and maintaining continuity of supply. For some, re-shoring advanced manufacturing processes proved capital intensive but strategically justified to secure critical intermediates and biologics output. For others, investing in dual-sourcing frameworks and inventory buffering provided a more flexible response to tariff volatility. In parallel, payers and distributors scrutinized price and reimbursement dynamics more closely, prompting some manufacturers to accelerate cost-efficiency programs and to pursue value demonstrations that emphasize total cost of care rather than unit price alone.

Overall, the tariff environment highlighted the need for integrated commercial and supply chain strategies that can withstand policy-driven shocks while preserving access and quality of hormone therapies across diverse care settings.

Comprehensive segmentation analysis that links hormone classes, therapeutic applications, enabling technologies, and end-user channels to actionable strategic priorities

Insight-driven segmentation clarifies where therapeutic and commercial opportunities converge and where operational risks concentrate. Based on hormone class, the market is studied across Estrogen, Insulin, and Thyroid, each representing distinct clinical pathways and manufacturing modalities that require tailored regulatory strategies and delivery approaches. Based on application, the market is studied across Contraception, Diabetes, Growth Hormone Deficiency, Menopausal Symptoms, and Thyroid Disorders; within this dimension, Contraception is further studied across Combined Oral Contraceptive and Progestin Only Contraceptive, Growth Hormone Deficiency is further studied across Adult GHD and Pediatric GHD, Menopausal Symptoms is further studied across Hot Flashes, Osteoporosis, and Vaginal Atrophy, and Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism, enabling fine-grained targeting of clinical indications and patient segments.

Based on technology, the market is studied across Chemical Synthesis and Recombinant DNA Technology; the Chemical Synthesis pathway is further studied across Liquid-Phase Synthesis and Solid-Phase Synthesis while the Recombinant DNA Technology pathway is further studied across Bacterial Expression Systems, Mammalian Cell Expression Systems, and Yeast Expression Systems, highlighting trade-offs between yield, post-translational modification fidelity, and cost of goods. Based on end user, the market is studied across Clinics, Homecare Settings, Hospitals, Online Pharmacies, and Retail Pharmacies; within that classification the Clinics category is further disaggregated into General Practice Clinics and Specialty Clinics, Homecare Settings into Nursing Service and Self-Administration, Hospitals into Private Hospitals and Public Hospitals, Online Pharmacies into Over-The-Counter and Prescription-Based models, and Retail Pharmacies into Chain Pharmacies and Independent Pharmacies, which clarifies distribution pathways, reimbursement touchpoints, and patient access considerations.

These segmentation lenses collectively enable stakeholders to prioritize investments, design differentiated clinical evidence strategies, and align manufacturing footprints with the specific demands of each therapeutic and channel combination.

Region-specific implications for regulation, manufacturing capacity, and commercial engagement across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics present distinctive regulatory, manufacturing, and commercial contours that influence strategic choices. In the Americas, advanced clinical ecosystems and strong insulin and contraceptive demand coexist with concentrated manufacturing clusters that prioritize biologics scale-up and advanced formulation capabilities. In Europe, Middle East & Africa, regulators increasingly harmonize biosimilar pathways while healthcare systems emphasize cost containment and access, prompting manufacturers to refine value dossiers and engage more deeply with regional health technology assessment processes. In Asia-Pacific, rapid adoption of recombinant technologies and growing capacity in both established and emerging manufacturing hubs are complemented by expanding private and public healthcare spending, creating competitive pressure and collaborative opportunities for contract manufacturing and local partnerships.

Across these regions, differences in reimbursement paradigms, clinical practice patterns, and supply chain resilience require tailored market entry and growth strategies. Regulatory alignment initiatives and regional trade agreements can create avenues for streamlined approvals and cross-border clinical collaboration, but local manufacturing capabilities and distribution networks remain decisive factors for ensuring timely patient access. Consequently, companies that develop region-specific pathways for evidence generation, regulatory engagement, and channel management are better positioned to convert scientific strengths into sustained commercial performance.

Critical competitive dynamics and partnership strategies that determine capacity, technological differentiation, and commercialization effectiveness in the hormone therapeutics sector

Competitive dynamics in synthetic hormones are shaped by a mix of multinational pharmaceutical corporations, specialized biotechnology firms, contract development and manufacturing organizations, and emerging innovators focused on novel delivery platforms. Leading biologics developers have leveraged investments in recombinant technologies and advanced cell expression systems to extend their presence across insulin analogs and growth hormone therapies, while traditional small-molecule manufacturers continue to refine chemical synthesis routes for peptide and steroid-based hormones.

Strategic collaboration between originators and contract manufacturers has intensified as companies seek modular capacity and flexible supply arrangements. Partnerships with technology providers that specialize in high-yield bacterial and mammalian expression systems, as well as firms that offer advanced formulation and device integration, are increasingly important for accelerating time to clinic and ensuring scalable production. Mergers and acquisitions activity concentrates on filling capability gaps, securing geographic manufacturing footprint, and acquiring differentiated delivery technologies that enhance patient adherence. The competitive landscape rewards organizations that combine scientific differentiation with operational excellence, evidenced by investments in regulatory compliance, quality management systems, and integrated data platforms that support lifecycle evidence generation.

Targeted and practical recommendations for leaders to strengthen resilience, accelerate commercialization, and align development with evolving care delivery models

Industry leaders should pursue a set of prioritized, actionable measures to strengthen resilience and accelerate value creation. First, align R&D priorities with delivery and manufacturing feasibility by selecting development pathways that balance clinical differentiation with cost-to-serve considerations, and by validating scalable production routes early in the lifecycle. Second, diversify sourcing across raw materials and intermediates and build contingency supply agreements or dual-sourcing arrangements to reduce vulnerability to policy-driven tariffs and logistic bottlenecks. Third, invest in regulatory strategy and post-market evidence generation to address biosimilarity concerns, long-term safety questions, and regional reimbursement requirements. These efforts should include proactive engagement with regulators and health technology assessment bodies to streamline market access.

Fourth, redesign commercial models to reflect evolving patient pathways by supporting homecare and self-administration programs, enabling remote monitoring, and leveraging prescription-based online channels to enhance adherence and reach underserved populations. Fifth, pursue strategic collaborations with contract manufacturers and technology partners to access specialized expression systems, formulation expertise, and device integration capabilities without the need for heavy capital outlays. Lastly, embed advanced analytics and quality-by-design principles across development and manufacturing to improve yield, reduce batch failures, and accelerate time-to-clinic. Executed together, these actions will enable companies to mitigate near-term disruptions while building differentiated, sustainable advantage.

Rigorous multi-method methodology combining primary stakeholder engagement, regulatory and patent analysis, and triangulated secondary evidence to ensure robust insights

The research methodology combines primary and secondary approaches to ensure robust, triangulated insights. Primary research encompassed structured interviews and in-depth discussions with stakeholders across the value chain including R&D leads, manufacturing heads, regulatory affairs specialists, commercial executives, clinical investigators, and payers. This qualitative input was complemented by systematic document analysis of regulatory guidance, clinical trial registries, patent landscapes, and publicly disclosed regulatory submissions to understand recent precedent and evidentiary expectations.

Secondary research drew on peer-reviewed literature, conference proceedings, technology white papers, and company disclosures to map technological trajectories and historical performance trends. Data synthesis followed a transparent triangulation process that reconciled divergent perspectives and tested hypotheses against multiple independent sources. Where appropriate, scenario analyses were used to examine the operational implications of supply chain disruptions, tariff changes, and regulatory shifts. Quality controls included cross-validation of interview findings, methodological audits, and review by domain experts to ensure the integrity and relevance of the conclusions presented.

Concise and forward-looking conclusion synthesizing strategic imperatives, operational risks, and opportunity pathways for synthetic hormone stakeholders

In summary, the synthetic hormones sector is at an inflection point where scientific capability, regulatory evolution, and shifting care models intersect. Advances in recombinant DNA technologies and improved chemical synthesis routes are unlocking new therapeutic options and enabling more patient-centric delivery modalities, yet these opportunities are counterbalanced by complex manufacturing requirements, evolving regulatory expectations, and policy-induced supply chain pressures. Stakeholders that proactively integrate evidence generation, regulatory engagement, and supply chain resilience into their strategic planning will be better equipped to translate innovation into scalable, cost-effective patient solutions.

Moving forward, success will depend on pragmatic alignment across R&D, manufacturing, and commercial functions, coupled with targeted partnerships that bring specialized capabilities without excessive capital commitments. By emphasizing flexible sourcing, robust quality systems, and patient-oriented distribution channels, organizations can navigate near-term disruptions while positioning themselves to capture long-term clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in personalized hormone replacement therapies using biosynthetic estradiol and testosterone analogues
  • 5.2. Integration of AI-driven molecular design to accelerate novel synthetic peptide hormone discovery
  • 5.3. Regulatory approvals driving adoption of long-acting depot formulations for synthetic GnRH analogues
  • 5.4. Rising investment in plant-based biosynthetic routes for sustainable progesterone production
  • 5.5. Expansion of synthetic insulin analogues with ultra-rapid-acting profiles for precise glycemic control
  • 5.6. Development of oral synthetic peptide hormones through permeability enhancers and nanocarriers
  • 5.7. Growth of telehealth prescribing platforms boosting demand for at-home hormone therapy kits
  • 5.8. Strategic partnerships between pharma and biotech to scale up chemoenzymatic hormone synthesis
  • 5.9. Advancements in continuous subcutaneous delivery systems for synthetic human growth hormone
  • 5.10. Market shift towards lab-grown microbial fermentation routes for cost-effective hGH production

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Synthetic Hormones Market, by Hormone Class

  • 8.1. Estrogen
  • 8.2. Insulin
  • 8.3. Thyroid

9. Synthetic Hormones Market, by Application

  • 9.1. Contraception
    • 9.1.1. Combined Oral Contraceptive
    • 9.1.2. Progestin Only Contraceptive
  • 9.2. Diabetes
  • 9.3. Growth Hormone Deficiency
    • 9.3.1. Adult GHD
    • 9.3.2. Pediatric GHD
  • 9.4. Menopausal Symptoms
    • 9.4.1. Hot Flashes
    • 9.4.2. Osteoporosis
    • 9.4.3. Vaginal Atrophy
  • 9.5. Thyroid Disorders
    • 9.5.1. Hyperthyroidism
    • 9.5.2. Hypothyroidism

10. Synthetic Hormones Market, by Technology

  • 10.1. Chemical Synthesis
    • 10.1.1. Liquid-Phase Synthesis
    • 10.1.2. Solid-Phase Synthesis
  • 10.2. Recombinant Dna Technology
    • 10.2.1. Bacterial Expression Systems
    • 10.2.2. Mammalian Cell Expression Systems
    • 10.2.3. Yeast Expression Systems

11. Synthetic Hormones Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Practice Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Homecare Settings
    • 11.2.1. Nursing Service
    • 11.2.2. Self-Administration
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals
  • 11.4. Online Pharmacies
    • 11.4.1. Over-The-Counter
    • 11.4.2. Prescription-Based
  • 11.5. Retail Pharmacies
    • 11.5.1. Chain Pharmacies
    • 11.5.2. Independent Pharmacies

12. Synthetic Hormones Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Synthetic Hormones Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Synthetic Hormones Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Johnson & Johnson
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Bristol Myers Squibb Company
    • 15.3.5. Sanofi SA
    • 15.3.6. AstraZeneca PLC
    • 15.3.7. Novo Nordisk A/S
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Teva Pharmaceutical Industries Ltd.
    • 15.3.10. Ferring B.V.
    • 15.3.11. Endo Pharmaceuticals Inc.
    • 15.3.12. Lupin Pharmaceuticals Inc.
    • 15.3.13. IBSA Institute Biochimique SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SYNTHETIC HORMONES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SYNTHETIC HORMONES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SYNTHETIC HORMONES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SYNTHETIC HORMONES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PROGESTIN ONLY CONTRACEPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ADULT GHD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PEDIATRIC GHD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOT FLASHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY VAGINAL ATROPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPERTHYROIDISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY LIQUID-PHASE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY MAMMALIAN CELL EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY NURSING SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY SELF-ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SYNTHETIC HORMONES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CHEMICAL SYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOMECARE SETTINGS, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS SYNTHETIC HORMONES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY HORMONE CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY CONTRACEPTION, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY MENOPAUSAL SYMPTOMS, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY THYROID DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA SYNTHETIC HORMONES MARKET SIZE, BY TECHNOLOGY, 2